Unicycive Therapeutics, Inc. Research And Development Expense

• Unicycive Therapeutics, Inc. showed a decrease of -54.4% in Research And Development Expense from 2024 to 2025.
• This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Unicycive Therapeutics, Inc.'s Research And Development Expense has grown by 798.6%.
• Historical annual values: Fiscal year 2025: $9.12 million | Fiscal year 2024: $20.01 million | Fiscal year 2023: $12.90 million | Fiscal year 2022: $12.44 million | Fiscal year 2021: $6.08 million | Fiscal year 2020: $1.02 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026